Parse Biosciences
Parse Biosciences is a Seattle-based life sciences tools company that builds instrument-free single-cell RNA sequencing kits and services based on its proprietary Evercode split-pool combinatorial barcoding technology, serving 3,000+ academic, biotech, and pharmaceutical research labs across 40+ countries; the company was acquired by QIAGEN in December 2025 for approximately $225 million.
- Company typePrivate
- Founded2019
- HeadquartersSeattle, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Parse Biosciences does
Parse Biosciences, founded in 2018 and headquartered in Seattle, develops scalable single-cell RNA sequencing solutions built on its proprietary Evercode™ split-pool combinatorial barcoding technology. The platform fixes and permeabilizes cells so they serve as their own reaction vessels, eliminating the need for microfluidic instruments or microwell arrays and enabling experiments from 10,000 to 5 million cells per run. The Evercode product family spans whole-transcriptome kits (WT Mini, WT, WT Mega, WT Penta, WT FFPE), immune profiling kits (TCR, BCR), fixation modules, CRISPR Detect pooled screens, and a Gene Select targeted panel; the GigaLab service tier delivers large-scale projects (10M+ cells) for AI-driven drug discovery customers such as Tahoe Therapeutics and Graph Therapeutics. The free Trailmaker cloud platform guides users from FASTQ files through publication-ready figures with native Seurat and Scanpy export.
The company sells through direct/website channels, a growing authorized distributor network, and service providers across 40+ countries, serving academic institutions, biotech, and pharmaceutical R&D organizations with a quote-based kit-plus-services model. As of December 2025, Parse was acquired by QIAGEN N.V. for approximately $225 million in cash (up to $280 million with milestones), with QIAGEN projecting approximately $40 million in 2026 sales contribution from the Parse business. Prior to the acquisition, the company had raised over $100 million across a Series B ($41.5M, 2022) led by Marshall Wace and Janus Henderson and a Series C ($50M, 2023) led by Soleus Capital, and had grown to serve 3,000+ labs. Following the acquisition, the Parse CEO departed and the brand operates as a subsidiary within QIAGEN's Sample technologies portfolio.
Parse Biosciences firmographics
Firmographics- Name
- Parse Biosciences
- Legal name
- Parse Biosciences
- Website
- https://parsebiosciences.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Acquired
- Headcount range
- 101–250 employees
- Short description
- Parse Biosciences is a Seattle-based life sciences tools company that builds instrument-free single-cell RNA sequencing kits and services based on its proprietary Evercode split-pool combinatorial barcoding technology, serving 3,000+ academic, biotech, and pharmaceutical research labs across 40+ countries; the company was acquired by QIAGEN in December 2025 for approximately $225 million.
- Ownership category
- akta.pro rank
Parse Biosciences industry classification
Industry- Product category
- Single Cell Sequencing Reagents
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF)
Keywords
Where Parse Biosciences is headquartered
LocationHeadquarters
- HQ city
- Seattle
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Parse Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain
Revenue model
- Evercode Kit Products: Sale of single cell sequencing reagent kits including Evercode WT Mini, WT, WT Mega, WT Penta, TCR, BCR, Fixation, Gene Select, and CRISPR Detect. Land-and-expand model as labs scale from small to large throughput kits.
- GigaLab Services: Large-scale single cell sequencing services for projects requiring 10M+ cells. Provides sequencing services using the GigaLab platform for drug discovery and AI-driven research.
- Trailmaker Platform: Free analysis platform included with kits. Provides end-to-end workflow from FASTQ files through publication-ready figures.
Go-to-market motion2 records
Distribution channels4 records
Marketing channels7 records
Parse Biosciences product offering
Product offeringCore offering
Parse Biosciences develops and sells instrument-free single cell RNA sequencing reagent kits built on its proprietary Evercode split-pool combinatorial barcoding technology. The product portfolio spans entry-level to ultra-high-throughput whole transcriptome kits, paired TCR/BCR immune profiling kits, fixation/sample preservation kits, and FFPE-compatible kits, complemented by GigaLab services for 10M+ cell projects and the Trailmaker cloud-based data analysis software.
Product overview
Parse Biosciences offers a comprehensive single cell sequencing platform based on proprietary Evercode split-pool combinatorial barcoding technology. The product portfolio centers on instrument-free single cell solutions ranging from entry-level (Evercode WT Mini, 10K cells) to ultra-high-throughput (Evercode WT Penta, 5M cells) whole transcriptome kits. Specialized immune profiling products include Evercode TCR and Evercode BCR for paired receptor sequencing. Supporting add-on modules include Gene Select for targeted panels, CRISPR Detect for pooled screens, Evercode Fixation for sample preservation, and Evercode Whole Blood Fixation for blood samples. FFPE-compatible Evercode WT FFPE enables analysis of archived tissue. The GigaLab service offering enables single cell sequencing at 10M+ cell scale. Trailmaker cloud platform provides end-to-end data analysis with integrated visualization and export to Seurat/Scanpy. The platform is sold directly and through a growing distributor network globally, with over 3,000 labs served. Parse was acquired by QIAGEN in late 2025.
Differentiator
Problem solved
Functional benefit
Brands
- Evercode: Scalable single cell sequencing technology platform using combinatorial barcoding, available in multiple formats including Whole Transcriptome, TCR, BCR, and FFPE variants.
- GigaLab
- Trailmaker
Products and services
- Evercode WT Mini
Quantifiable outcome
- 27.5% more transcripts per cell detected vs Chromium GEM-X at 40,000 reads/cell
- +5 more outcomes
Companies that use Parse Biosciences
Customer profileNamed customers20 records
Segments3 records
Ideal customer profiles3 records
Parse Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
Feature6 records
Parse Biosciences partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core, flagship and minor.
- bit.biocoreLandmark alliance combining massively parallel single cell perturbation with bit.bio's cell programming to build foundational map of transcription factor-driven cell fate. Alliance powers AI-driven predictive medicine and human cell manufacturing by linking genetic inputs to cellular outputs.
- Graph TherapeuticscoreStrategic partnership to create one of the largest immune cell perturbation atlases. Combines Graph's lab-in-the-loop AI platform with Parse's GigaLab single cell technology to profile hundreds of millions of cells from patients with immune diseases. Aims to accelerate AI-first drug discovery by revealing diverse immune and tissue interactions.
- Codebreaker LabscoreCollaboration to develop a platform combining Codebreaker's synthetic biology variant engineering capabilities with Parse's Evercode single cell technology. Enables parallel testing of thousands of genetic variants at single cell resolution to generate causal data for rare and private variants that traditional observational studies cannot analyze.
- Tahoe TherapeuticscoreParse provides GigaLab single cell sequencing services for Tahoe Therapeutics' 300 million cell project to generate the largest perturbation-focused single cell dataset for AI-driven drug discovery. Project aims to train AI algorithms with unprecedented scale.
- QIAGENflagshipQIAGEN acquired Parse Biosciences in December 2025 for approximately $225 million in cash, with potential milestone payments up to $280 million total. The acquisition strengthens QIAGEN's Sample technologies portfolio into highly scalable single-cell solutions. Parse operates as a QIAGEN company while maintaining its brand identity.
- Third Rock Ventures-backed CompanyminorCollaboration with stealth Third Rock Ventures-backed company developing precision medicines for autoimmune disease. Uses Parse's GigaLab platform to create large atlas of 5 million T cell receptors (TCRs) to enhance understanding of autoimmune illnesses and accelerate drug discovery.
- International Research PartnersminorExpanding presence in international markets including Australia, Europe, India, Israel, New Zealand, Singapore, and South Korea through distribution partnerships to meet increasing demand from global research markets.
Scale indicators9 records
Recent moves6 records
Expansion highlights6 records
Parse Biosciences competitors and assessment
Company assessmentDirect peers
- 10x Genomics: The dominant player in single-cell sequencing with the Chromium droplet-based platform. Direct competitor to Parse's Evercode technology, with the largest installed base of instruments in academic and pharma research labs. Parse's marketing materials explicitly position Evercode against Chromium with head-to-head sensitivity and multiplet rate comparisons.
- BD (Becton Dickinson): Offers the BD Rhapsody single-cell analysis system, a competing platform to Parse's Evercode using a different microwell-based barcoding approach. Targets similar academic and translational research customers and is referenced in Parse's competitive comparisons.
- Standard BioTools (formerly Fluidigm): Long-standing player in single-cell genomics with the C1 and Hyperion imaging mass cytometry platforms. Operates in adjacent single-cell analysis segments and serves similar academic research customers, though at smaller scale than 10x or Parse.
Broad incumbents
- Illumina: Dominant sequencing platform provider whose instruments are used downstream of Parse's library prep kits. While not a direct single-cell library prep competitor, Illumina's strategic moves in library prep and partnerships with other single-cell companies affect Parse's market dynamics and sequencer compatibility.
- Bio-Techne: Provides reagents, kits, and analytical tools for life science research including single-cell workflows. Overlaps with Parse through the consumables and reagent product category, particularly in proteomics-adjacent single-cell applications.
- QIAGEN: Parent company of Parse following the December 2025 acquisition. Offers sample technologies, NGS library prep, and bioinformatics for molecular biology. Provides global distribution, customer relationships, and complementary products that will accelerate Parse's commercial reach.
Emerging players
- Mission Bio: Single-cell genomics platform focused on DNA-level analysis (Tapestri), particularly for oncology applications and clonal heterogeneity. Competes in adjacent single-cell use cases (DNA rather than RNA) and serves similar translational research customers.
- Akoya Biosciences: Spatial biology company offering single-cell resolution tissue analysis. Adjacent to Parse's single-cell RNA sequencing business, with overlap in immuno-oncology and translational research customer segments.
- Ultima Genomics: Sequencing platform provider whose UG100 instrument is used in Parse's GigaLab workflows. Currently a technology partner, but a potential competitive threat if Ultima develops native single-cell library prep capabilities or expands into upstream sample prep.
- Bruker (NanoString spatial biology): Following its acquisition of NanoString, Bruker offers spatial transcriptomics and single-cell analysis solutions (CosMx, GeoMx). Competes in adjacent single-cell and tissue analysis markets with overlap in academic and translational research customers.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Parse Biosciences social profiles
Digital presenceParse Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Parse Biosciences leadership team
Management profileNumber of profiles
Profiles6 records
Parse Biosciences funding detail
Funding detailFunding overview
Funding rounds6 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Parse Biosciences M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Parse Biosciences
What does Parse Biosciences do?
Parse Biosciences develops and sells instrument-free single cell RNA sequencing reagent kits built on its proprietary Evercode split-pool combinatorial barcoding technology. The product portfolio spans entry-level to ultra-high-throughput whole transcriptome kits, paired TCR/BCR immune profiling kits, fixation/sample preservation kits, and FFPE-compatible kits, complemented by GigaLab services for 10M+ cell projects and the Trailmaker cloud-based data analysis software.
Is Parse Biosciences a public or private company?
Parse Biosciences is a private company. It is classified as corporate owned and is currently acquired.
When was Parse Biosciences founded?
Parse Biosciences was founded in 2019. It employs 101 to 250 people.
Where is Parse Biosciences based?
Parse Biosciences is headquartered in Seattle, United States, in the North America region.
How does Parse Biosciences make money?
Three revenue lines are on record. Evercode Kit Products are the primary driver. The others are gigaLab Services and trailmaker Platform.
Who are Parse Biosciences's main competitors?
Direct peers on record are 10x Genomics, BD (Becton Dickinson) and Standard BioTools (formerly Fluidigm). Broad incumbents are Illumina, Bio-Techne and QIAGEN. Emerging players are Mission Bio, Akoya Biosciences, Ultima Genomics and Bruker (NanoString spatial biology).
Does Parse Biosciences have an API?
No public API is recorded for Parse Biosciences.
What industry is Parse Biosciences in?
Parse Biosciences's product category is Single Cell Sequencing Reagents. Its primary akta.pro industry code is HLAGAIAF, Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays). Its NAICS code is 325414 and its SIC code is 2836.